Recent news on Levetiracetam

Alembic seals epilepsy drug delivery deal  -  May 24, 2007
In-PharmaTechnologist.com,The extended release version of UCB's Keppra (levetiracetam) is currently in Phase III trials with results expected by the end of this year, and promises to

Women Taking Antiepileptics Give Birth to Babies at Risk ...  -  May 4, 2007
DG NewsAntiepileptic drugs observed in this study included valproate, lamotrigine, carbamazepine, levetiracetam, phenytoin, oxcarbazepine, gabapentin,

New drug shows promise for epilepsy  -  Apr 6, 2007
Science Daily (press release)Analysis: Newer/older epilepsy drugs equal (February 5, 2007) -- In a head-to-head comparison, the newer anti-epileptic drug levetiracetam -- marketed as

Phase III Results For Keppra® As Adjunctive Therapy For Partial ...  -  Apr 24, 2007
Medical News Today (press release),...double-blind, randomized, multi-centre, placebo-controlled study evaluating the efficacy and tolerability of Keppra® (levetiracetam) (20-50 mg/kg/day)

Keppra Approved for Additional Indication  -  Mar 27, 2007
Facts and Comparisons,The FDA has approved an additional indication for UCB Pharma’s Keppra (levetiracetam) tablets and oral solution. The new indication provides for the use of

Keppra® Approved For US Epilepsy Patients With One Of The Most ...  -  Mar 29, 2007
Medical News Today (press release),The US Food and Drug Administration (FDA) has approved UCB's leading anti-epileptic drug Keppra® (levetiracetam), as adjunctive therapy in the treatment of

TODAY ON PHARMALIVE.COM  -  Apr 20, 2007
PharmaLive.com (press release),...double-blind, randomized, multi-centre, placebo-controlled study evaluating the efficacy and tolerability of Keppra® (levetiracetam) (20-50 mg/kg/day)

UCB Announces Positive Top-Line Phase III Results for Keppra(R) as ...  -  Apr 20, 2007
Web Services Journal,...multi-centre, placebo-controlled study evaluating the efficacy and tolerability of Keppra® (levetiracetam) (20- 50 mg/kg/day) as adjunctive therapy in

New Treatment Option for Epilepsy Patients With One of the Most ...  -  Mar 29, 2007
Drug Newswire (press release),Drug Administration (FDA) yesterday approved UCB's leading anti-epileptic drug Keppra(R) (levetiracetam) tablets and oral solution as adjunctive therapy

Keppra(R) Approved for US Epilepsy Patients with One of the Most ...  -  Mar 20, 2007
SYS-CON Media,Rosenfeld WE, Berkovic S, Knowlton R on behalf of Lev N01057 PGTC Study Group - Efficacy and Safety of Levetiracetam 3000 mg/day (Padiatric Dose 60

Keppra(R) Approved for US Epilepsy Patients with One of the Most ...  -  Mar 20, 2007
Genetic Engineering News (press release),The US Food and Drug Administration (FDA) has approved UCB's leading anti-epileptic drug Keppra(R) (levetiracetam), as adjunctive therapy in the treatment

UCB's Cimzia faces severe delay as new study is needed  -  Mar 23, 2007
Pharma Times (subscription),...protection on its biggest earners - the allergy drug Zyrtec (cetirizine) and the antiepileptic Keppra (levetiracetam) - in 2007 and 2009 respectively.

FDA extends use of UCB's antiepileptic Keppra  -  Mar 21, 2007
Pharma Times (subscription),Keppra (levetiracetam) has been on the market since 2000 as an adjunct treatment for partial onset seizures in patients aged four and above, and last summer

New Treatment Option For Epilepsy Patients With One Of The Most ...  -  Mar 21, 2007
Medical News Today (press release),The US Food and Drug Administration (FDA) yesterday approved UCB's leading anti-epileptic drug Keppra(R) (levetiracetam) tablets and oral solution as

New Treatment Option for Epilepsy Patients With One of the Most ...  -  Mar 20, 2007
Compliance Home,...(March 20, 2007)--The FDA approved UCB's leading anti-epileptic drug Keppra (levetiracetam) tablets and oral solution as adjunctive therapy in the treatment

New Treatment Option for Epilepsy Patients With One of the Most ...  -  Mar 20, 2007
PR Newswire (press release),Drug Administration (FDA) yesterday approved UCB's leading anti-epileptic drug Keppra(R) (levetiracetam) tablets and oral solution as adjunctive therapy

Treatment-Resistant Bipolar Disorder  -  Mar 15, 2007
Focus (subscription)Four open studies, with an aggregate of 79 subjects, have examined the potential efficacy of levetiracetam in bipolar disorder (29 –32).

Migraine prophylactic ups job productivity  -  Mar 15, 2007
Science Daily (press release)2007) -- Scottish scientists say newly diagnosed epilepsy patients experience few, if any, seizures while taking the drug levetiracetam as a single .

UCB pins its hopes on Cimzia for future growth  -  Mar 1, 2007
Pharma Times (subscription),The main driver of growth once again was the antiepileptic Keppra (levetiracetam), which saw its dominant position in the US market reinforced through new

Levetiracetam shows promise for epilepsy  -  Feb 5, 2007
News-Medical.net,People with newly diagnosed epilepsy experienced few, if any, seizures while taking the drug levetiracetam as a single therapy, giving hope to epilepsy

Levetiracetam monotherapy shows promise for newly diagnosed epilepsy  -  Feb 6, 2007
Therapeutics Daily (subscription) (press release),NEW YORK (Reuters Health) - Low-dose levetiracetam appears to be an effective monotherapy for newly diagnosed epilepsy, with seizure freedom rates

No more seizures? New drug holds promise for epilepsy patients  -  Feb 6, 2007
PressZoom (press release),While levetiracetam is currently used as an add-on therapy by epilepsy patients, this is the first time its effectiveness as a single therapy has been

Keppra promising for newly diagnosed epilepsy  -  Feb 6, 2007
ReutersNEW YORK (Reuters Health) - Treatment with low doses of levetiracetam, the active ingredient in the drug Keppra, appears to be effective by itself for

No More Seizures? New Drug Holds Promise For Epilepsy Patients  -  Feb 6, 2007
Science Daily (press release)Science Daily — People with newly diagnosed epilepsy experienced few, if any, seizures while taking the drug levetiracetam as a single therapy,

No More Seizures? New Drug Holds Promise for Epilepsy Patients  -  Feb 6, 2007
DG NewsPAUL, MN -- February 6, 2007 -- People with newly diagnosed epilepsy experienced few, if any, seizures while taking the drug levetiracetam as a single

Single therapy holds promise for epilepsy patients  -  Feb 6, 2007
Pharmaceutical Business ReviewA study supported by UCB Pharma has demonstrated that administration with levetiracetam in people with newly diagnosed epilepsy experienced few, if any,

Analysis: Newer/older epilepsy drugs equal  -  Feb 5, 2007
Science Daily (press release)..."This study is the first to clearly demonstrate that levetiracetam is as effective as an older, commonly prescribed anti-seizure agent, carbamazepine,

Drug Promising for Epilepsy  -  Feb 5, 2007
Ivanhoe,New research reveals taking the drug levetiracetam (Keppra) alone may be a good alternative for patients who don't do well with current seizure medications.

UPI NewsTrack Health and Science News  -  Feb 6, 2007
United Press International6 (UPI) -- Scottish scientists say newly diagnosed epilepsy patients experience few, if any, seizures while taking the drug levetiracetam as a single

Epilepsy drug effective as single therapy  -  Feb 6, 2007
Monsters and Critics.com,For the double-blind study, researchers assigned nearly 600 adults who had at least two seizures during the previous year to the drug levetiracetam or to

First Time May Be Charm for Anti-Epileptic Drugs  -  Feb 5, 2007
MedPage Today,..."Levetiracetam and controlled-release carbamazepine produced equivalent seizure freedom rates in newly diagnosed epilepsy at optimal dosing in a setting

UCB presents promising Phase III data for Cimzia  -  Feb 23, 2007
Pharma Times (subscription),...in a number of indications before one of its key growth drivers, the antiepileptic Keppra (levetiracetam) starts to lose patent protection in 2009.

Pediatric studies lead to more information on drug labels  -  Feb 1, 2007
AAP News (subscription)Labeling changes for orlistat, sumatriptan, methylphenidate, mixed amphetamine salts and levetiracetam will assist the practitioner in choosing therapies

Positive Phase III data for Schwarz Pharma's lacosamide  -  Feb 16, 2007
Pharma Times (subscription),...as it is facing the loss of patent protection on key products such as the antihistamine Zyrtec (cetirizine) and the antiepileptic Keppra (levetiracetam).

Epilepsy drug effective as single therapy  -  Feb 6, 2007
Science Daily (press release)...if any, seizures while taking the drug levetiracetam as a single therapy, giving hope to epilepsy patients who don't respond to or can't tolerate .

FDA Safety Changes: Keppra, Naropin, Rebetol  -  Dec 22, 2006
Medscape (subscription)December 22, 2006 — The US Food and Drug Administration (FDA) has approved safety label revisions to advise of the expected similarity of levetiracetam's

More European Patients With Epilepsy to Benefit From Keppra(R)  -  Jan 16, 2007
Market Wire (press release)The European Commission (EC) has approved Keppra® (levetiracetam), as adjunctive therapy for the treatment of primary generalised tonic-clonic (PGTC)

FDA Safety Changes: Keppra, Naropin, Rebetol  -  Dec 22, 2006
Medscape (subscription)December 22, 2006 — The US Food and Drug Administration (FDA) has approved safety label revisions to advise of the expected similarity of levetiracetam's

Infusion Duration of Intravenous Levetiracetam the Same for Both ...  Sep 20, 2006
Children with epilepsy aged 4 years and older will experience the predicted range of plasma concentrations after IV administration of levetiracetam, and should ... -DG News

Levetiracetam Is Noninferior to Controlled-Release Carbamazepine ...  Sep 5, 2006
UK -- September 5, 2006 -- At optimal dosing levels and in a setting mimicking clinical practice, the novel antiepileptic drug levetiracetam is noninferior to ... -DG News

FDA Approvals: Keppra and Revlimid  Sep 7, 2006
September 7, 2006 — The US Food and Drug Administration (FDA) has approved new indications for levetiracetam, allowing its use as adjunctive therapy for the ... -Medscape (subscription)

Epilepsy Common in Patients With Low-Grade Glioma: Presented at ...  Sep 5, 2006
The review also found that antiepileptic agent levetiracetam is the most frequently used add-on drug in patients with refractory epilepsy, and it shows an ... -DG News

US FDA approves Keppra as adjunctive therapy in juvenile myoclonic ...  Sep 14, 2006
UCB announced that the US Food & Drug Administration (FDA) has approved the use of Keppra (levetiracetam) as adjunctive therapy in the treatment of myoclonic ... -Therapeutics Daily (subscription)

CHMP Adopts Positive Opinion Recommending Approval of Keppra(R ...  -  Nov 23, 2006
DG NewsEfficacy and safety of levetiracetam as adjunctive treatment in adult and paediatric patients suffering from idiopathic generalized epilepsy with primary

CHMP Adopts Positive Opinion Recommending Approval of Keppra® as ...  -  Nov 24, 2006
PipelineReview.com (press release),Commission grant a marketing authorisation for Keppra® (levetiracetam) as adjunctive therapy in the treatment of primary generalised tonic-clonic (PGTC)

The Committee gave positive opinions for applications for ...  -  Nov 21, 2006
Easy Bourse (Communiqués de presse),Keppra (levetiracetam), from UCB SA, to include the treatment of primary generalised tonic-clonic seizures as adjunctive therapy in adults and adolescents

A Key Regulatory Milestone for Keppra(R)  Jul 3, 2006
Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion to approve marketing authorisation of Keppra(R) (levetiracetam) as monotherapy ... -International News Service

Pediatric studies lead to label changes for more than 100 drugs ...  Jun 30, 2006
Two agents were tested and found to have efficacy in the treatment of children with epilepsy: levetiracetam (Keppra) and oxcarbazepine (Trileptal). ... -AAP News (subscription)

Epilepsy Diagnosis and Management  Jun 22, 2006
Two thirds of the patients were controlled with monotherapy. Gabapentin and levetiracetam were the most frequently used antiepileptic drugs. ... -Medscape (subscription)

European Medicines Agency - Committee For Medicinal Products For ...  Jul 2, 2006
Keppra (levetiracetam), from UCB SA, to extend its indication to monotherapy in the treatment of partial onset seizures with or without secondary ... -Medical News Today

UCB boasts of new regulatory milestone for Keppra  Jul 4, 2006
The panel's positive opinion concerns the use of Keppra (levetiracetam) as monotherapy in the treatment of partial onset seizures with or without secondary ... -Pharmaceutical Business Review



Euronext Brussels) - UCB - European Commission Approves Keppra® ...  May 15, 2006
Brussels (Belgium) - May 15, 2006 - Today UCB announced that the European Commission has approved the use of Keppra® (levetiracetam) as adjunctive therapy in ... - Euronext (persbericht)

HUGIN NEWS/UCB: Two European Regulatory Milestones for Keppra®  Apr 25, 2006
Brussels (BELGIUM) April 26, 2006 - Today UCB announced that the European Commission has approved the use of Keppra® (levetiracetam) 100 mg/mL concentrate for ... - Frankfurter Allgemeine Zeitung

UCB: IV Keppra Gets EU Regulatory Nod  Apr 27, 2006
With the European Commission's approval of an intravenous (IV) formulation of Keppra (levetiracetam) for use as adjunctive therapy in the treatment of epilepsy ... - International News Service

Anticonvulsant Treatment for Psychiatric and Seizure Indications ...  May 4, 2006
...related products), gabapentin, oxcarbazepine, lamotrigine, topiramate, phenytoin, selected barbiturates, succinimides, tiagabine, levetiracetam, and felbamate. ... - Psychiatric Services (subscription)





Positive Clinical Trial Results for Keppra as Monotherapy ...  Apr 5, 2006
...non-inferiority trial presented this week at the annual meeting of the American Academy of Neurology (AAN) demonstrated that Keppra (levetiracetam) was non ... - PharmaLive.com

European Medicines Agency: Committee for Medicinal Products for ...  Mar 24, 2006
...chemotherapy. § Keppra (levetiracetam), from UCB SA, to add treatment of myoclonic seizures in patients with juvenile myoclonic epilepsy. ... - PharmaLive.com



UCB Receives EMEA Positive Opinion and FDA Approvable Letter for ...  Feb 6, 2006
CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion to approve marketing authorisation of Keppra® (levetiracetam) Concentrate (100 mg ... - Chemie.de

Keppra as adjunctive treatment in idiopathic generalised epilepsy ...  Jan 21, 2006
IGE ) having primary generalised tonic-clonic ( PGTC ) seizures became free from all types of seizures when Keppra ( Levetiracetam ) was administered as an add ... - Xagena.it

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional